<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122860</url>
  </required_header>
  <id_info>
    <org_study_id>SM04690-OA-04</org_study_id>
    <nct_id>NCT03122860</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis</brief_title>
  <official_title>A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosplice Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosplice Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 study is a placebo-controlled, double-blind, parallel group study of four&#xD;
      concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected&#xD;
      intraarticularly (IA) into the target knee joint of subjects with moderately to severely&#xD;
      symptomatic osteoarthritis (OA). Based on previous studies of SM04690, key phenotypes of&#xD;
      laterality (unilateral vs bilateral) as well as chronic pain (as measured by the Widespread&#xD;
      Pain Index) were identified as confounding variables impacting the overall assessment of both&#xD;
      radiologic and clinical efficacy outcomes. The design of SM04690-OA-04 is based upon previous&#xD;
      study designs while assessing strategies to combat the confounding impact of laterality and&#xD;
      chronic pain. To evaluate the effect of IA vehicle injection on patient-reported outcomes&#xD;
      (PRO) such as pain, stiffness, and function in OA, this study also includes one cohort that&#xD;
      receives a 2 mL IA injection of vehicle (placebo), and one cohort that receives a sham&#xD;
      injection (i.e., a needle stick with 0 mL vehicle injected).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Osteoarthritis (OA) Pain in the Target Knee as Assessed by the Weekly Average of Daily Pain Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 24. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline OA Pain in the Target Knee as Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain; 100 = pain as bad as it can be].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Medial Joint Space Width (mJSW) of the Target Knee</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in mJSW as documented by radiograph of the target knee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline OA disease activity as assessed by PtGA at Week 24. The PtGA was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Pain in the Target Knee as Assessed by WOMAC Pain Subscore (WOMAC Pain)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain, 100 = pain as bad as it can be].</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Pain in the Target Knee as Assesses by the Weekly Average of Daily Pain NRS</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 12. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline OA disease activity as assessed by PtGA at Week 12. The PtGA completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>0.03 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.07 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.15 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.23 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04690</intervention_name>
    <description>Healthcare professional-administered intra-articular injection performed once on Day 1 of the study</description>
    <arm_group_label>0.03 mg SM04690</arm_group_label>
    <arm_group_label>0.07 mg SM04690</arm_group_label>
    <arm_group_label>0.15 mg SM04690</arm_group_label>
    <arm_group_label>0.23 mg SM04690</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Healthcare professional-administered intra-articular injection performed once on Day 1 of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Healthcare professional-administered intra-articular injection performed once on Day 1 of the study</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
          -  Diagnosis of femorotibial OA in the target knee by standard American College of&#xD;
             Rheumatology (ACR) criteria at screening (clinical AND radiographic criteria); OA of&#xD;
             the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid&#xD;
             arthritis)&#xD;
&#xD;
          -  Pain compatible with OA of the knee(s) for at least 26 weeks prior to screening&#xD;
&#xD;
          -  Primary source of pain throughout the body is due to OA in the target knee&#xD;
&#xD;
          -  Willingness to use an electronic diary on a daily basis in the evening for the&#xD;
             screening period and 24-week study duration&#xD;
&#xD;
          -  Negative drug test for opioids and drugs of abuse, except alcohol and marijuana, at&#xD;
             screening&#xD;
&#xD;
          -  Subjects with depression or anxiety must be clinically stable for 12 weeks prior to&#xD;
             screening, and, if on treatment for depression or anxiety, be on 12 weeks of stable&#xD;
             therapy&#xD;
&#xD;
          -  Full understanding of the requirements of the study and willingness to comply with all&#xD;
             study visits and assessments&#xD;
&#xD;
          -  Subjects must have read and understood the informed consent form, and must have signed&#xD;
             it prior to any study-related procedure being performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, lactating, or have a positive pregnancy result at screening&#xD;
&#xD;
          -  Women of child bearing potential who are sexually active and are not willing to use a&#xD;
             highly effective method of birth control during the study period&#xD;
&#xD;
          -  Males who are sexually active and have a partner who is capable of becoming pregnant,&#xD;
             neither of whom have had surgery to become sterilized or whom are not using a highly&#xD;
             effective method of birth control&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 35&#xD;
&#xD;
          -  Partial or complete joint replacement in either knee&#xD;
&#xD;
          -  Currently requires regular use of ambulatory assistive devices (e.g., wheelchair,&#xD;
             parallel bars, walker, canes, or crutches) or use of a lower extremity prosthesis,&#xD;
             and/or a structural knee brace&#xD;
&#xD;
          -  Previous participation in a Samumed clinical trial investigating SM04690&#xD;
&#xD;
          -  Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to screening&#xD;
&#xD;
          -  Any planned surgery during the study period&#xD;
&#xD;
          -  History of malignancy within the last 5 years; however, subjects with prior history of&#xD;
             in situ cancer or basal or squamous cell skin cancer are eligible if completely&#xD;
             excised. Subjects with other malignancies are eligible if they have been continuously&#xD;
             disease free for at least 5 years prior to any study injection&#xD;
&#xD;
          -  Comorbid conditions that could affect study endpoint assessments of the target knee,&#xD;
             including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic&#xD;
             lupus erythematosus, gout or pseudogout, and fibromyalgia&#xD;
&#xD;
          -  Any diagnosed psychiatric condition that includes, but is not limited to, a history of&#xD;
             mania, bipolar disorder, psychotic disorder, schizophrenia, schizoaffective disorder,&#xD;
             major depressive disorder, or generalized anxiety disorder&#xD;
&#xD;
          -  Participation in a clinical research trial that included the receipt of an&#xD;
             investigational product or any experimental therapeutic procedure, or an observational&#xD;
             research trial related to osteoarthritis within 8 weeks prior to any study injection,&#xD;
             or planned participation in any such trial&#xD;
&#xD;
          -  Treatment of the target knee with intra-articular glucocorticoids (e.g.,&#xD;
             methylprednisolone) within 12 weeks prior to screening&#xD;
&#xD;
          -  Any intra-articular injection into the target knee with a therapeutic aim including,&#xD;
             but not limited to, viscosupplementation (e.g., hyaluronic acid), platelet-rich plasma&#xD;
             (PRP), and stem cell therapies within 24 weeks prior to screening; treatment of the&#xD;
             target knee with intra-articular glucocorticoids greater than 12 weeks prior to&#xD;
             screening is allowed&#xD;
&#xD;
          -  Treatment with systemic glucocorticoids greater than 10 mg prednisone or the&#xD;
             equivalent per day within 4 weeks prior to screening&#xD;
&#xD;
          -  Effusion of the target knee clinically requiring aspiration within 12 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within&#xD;
             4 weeks prior to screening&#xD;
&#xD;
          -  Any known active infections, including urinary tract infection, upper respiratory&#xD;
             tract infection, sinusitis, suspicion of intra-articular infection, hepatitis B or&#xD;
             hepatitis C infection, and/or infections that may compromise the immune system such as&#xD;
             human immunodeficiency virus (HIV) at study start&#xD;
&#xD;
          -  Use of centrally acting analgesics (e.g., duloxetine) within 12 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  Use of anticonvulsants within 12 weeks prior to screening, unless used for seizure or&#xD;
             migraine prophylaxis&#xD;
&#xD;
          -  Subjects requiring the usage of opioids &gt;1x per week within 12 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  Use of topical local anesthetic agents (gels, creams, or patches such as the Lidoderm&#xD;
             patch) for the treatment of knee OA within 7 days of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biosplice Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jefferson</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage. 2021 May;29(5):654-666. doi: 10.1016/j.joca.2021.02.004. Epub 2021 Feb 12.</citation>
    <PMID>33588087</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <results_first_submitted>March 19, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <disposition_first_submitted>May 10, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 18, 2021</disposition_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SM04690</keyword>
  <keyword>Wnt pathway inhibitor</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>Samumed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorecivivint</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03122860/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03122860/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Full Analysis Set (FAS) includes all subjects who were randomized and received a study injection, analyzed as randomized.</recruitment_details>
      <pre_assignment_details>The Safety Analysis Set (SAS) [see 'Adverse Events' section] includes all subjects who received a study injection, analyzed as treated. Discrepancy in subject counts between FAS and SAS is the result of subjects who received a treatment that is different from the planned treatment group as randomized. Subjects who received a study treatment not as prescribed in the pharmacy manual are summarized in the &quot;Other&quot; treatment group for safety analysis reporting.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.03 mg SM04690</title>
          <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="P2">
          <title>0.07 mg SM04690</title>
          <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="P3">
          <title>0.15 mg SM04690</title>
          <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="P4">
          <title>0.23 mg SM04690</title>
          <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="P6">
          <title>Sham</title>
          <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="116"/>
                <participants group_id="P5" count="117"/>
                <participants group_id="P6" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="115"/>
                <participants group_id="P4" count="116"/>
                <participants group_id="P5" count="116"/>
                <participants group_id="P6" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="105"/>
                <participants group_id="P5" count="102"/>
                <participants group_id="P6" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued Before Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who were randomized and received a study injection, analyzed as randomized (Full Analysis Set [FAS]). FAS is used to describe the analysis set which is as complete as possible and as close as possible to the intent-to-treat ideal of including all randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>0.03 mg SM04690</title>
          <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="B2">
          <title>0.07 mg SM04690</title>
          <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="B3">
          <title>0.15 mg SM04690</title>
          <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="B4">
          <title>0.23 mg SM04690</title>
          <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="B6">
          <title>Sham</title>
          <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="115"/>
            <count group_id="B4" value="116"/>
            <count group_id="B5" value="116"/>
            <count group_id="B6" value="117"/>
            <count group_id="B7" value="695"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="7.9"/>
                    <measurement group_id="B2" value="59.9" spread="8.6"/>
                    <measurement group_id="B3" value="58.4" spread="8.3"/>
                    <measurement group_id="B4" value="58.5" spread="9.0"/>
                    <measurement group_id="B5" value="60.1" spread="9.0"/>
                    <measurement group_id="B6" value="59.0" spread="8.0"/>
                    <measurement group_id="B7" value="59.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="70"/>
                    <measurement group_id="B7" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="100"/>
                    <measurement group_id="B6" value="93"/>
                    <measurement group_id="B7" value="580"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="86"/>
                    <measurement group_id="B7" value="517"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>BMI was not collected for one participant in the 0.03 mg SM04690 cohort.</population>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="694"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.17" spread="3.76"/>
                    <measurement group_id="B2" value="29.14" spread="3.64"/>
                    <measurement group_id="B3" value="29.38" spread="4.10"/>
                    <measurement group_id="B4" value="28.53" spread="4.39"/>
                    <measurement group_id="B5" value="28.62" spread="4.29"/>
                    <measurement group_id="B6" value="28.97" spread="3.84"/>
                    <measurement group_id="B7" value="28.97" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kellgren-Lawrence Grade</title>
          <description>Participants' knee osteoarthritis was graded in accordance with the following definitions of Kellgren-Lawrence Grade: None (Grade 0) - Normal appearance of the knee; Doubtful (Grade 1): Doubtful narrowing of joint space and possible osteophytic lipping; Minimal (Grade 2): Definite osteophytes and possible narrowing of joint space; Moderate (Grade 3): Moderate multiple osteophytes, definite narrowing of the joint space, some sclerosis and possible deformity of bone ends; Severe (Grade 4): Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="57"/>
                    <measurement group_id="B7" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="72"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="398"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Osteoarthritis Laterality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Unilateral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bilateral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Widespread Pain (WP)</title>
          <description>Subjects were required to complete the Widespread Pain Index &amp; Symptom Severity questionnaire. The Widespread Pain Index (WPI) is a body map consisting of 19 prespecified areas where subjects can indicate the presence of pain during the past seven days with a possible score 0-19. Question 2 of the Symptom Severity section of the questionnaire (SSQ2) focuses on the presence and severity of three prespecified symptoms (fatigue, trouble thinking or remembering, and waking up tired) during the past seven days with a possible score of 0-9. WP+: WPI &gt; 4 and/or SSQ2 &gt; 2, WP-: WPI &lt;= 4 and SSQ2 &lt;= 2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="116"/>
                    <count group_id="B2" value="115"/>
                    <count group_id="B3" value="115"/>
                    <count group_id="B4" value="116"/>
                    <count group_id="B5" value="116"/>
                    <count group_id="B6" value="117"/>
                    <count group_id="B7" value="695"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>WP-</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="93"/>
                    <measurement group_id="B6" value="94"/>
                    <measurement group_id="B7" value="555"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WP+</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Osteoarthritis (OA) Pain in the Target Knee as Assessed by the Weekly Average of Daily Pain Numeric Rating Scale (NRS)</title>
        <description>Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 24. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Osteoarthritis (OA) Pain in the Target Knee as Assessed by the Weekly Average of Daily Pain Numeric Rating Scale (NRS)</title>
          <description>Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 24. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="2.44"/>
                    <measurement group_id="O2" value="-2.93" spread="2.21"/>
                    <measurement group_id="O3" value="-2.43" spread="2.18"/>
                    <measurement group_id="O4" value="-3.03" spread="2.43"/>
                    <measurement group_id="O5" value="-2.26" spread="2.44"/>
                    <measurement group_id="O6" value="-2.21" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.780</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline OA Pain in the Target Knee as Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain)</title>
        <description>Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain; 100 = pain as bad as it can be].</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Pain in the Target Knee as Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain)</title>
          <description>Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain; 100 = pain as bad as it can be].</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" spread="22.8"/>
                    <measurement group_id="O2" value="-30.0" spread="22.5"/>
                    <measurement group_id="O3" value="-24.7" spread="21.6"/>
                    <measurement group_id="O4" value="-33.3" spread="22.9"/>
                    <measurement group_id="O5" value="-25.5" spread="25.8"/>
                    <measurement group_id="O6" value="-22.5" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.612</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.32</ci_lower_limit>
            <ci_upper_limit>4.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.223</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.47</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.590</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.89</ci_lower_limit>
            <ci_upper_limit>8.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.03</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.70</ci_lower_limit>
            <ci_upper_limit>3.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)</title>
        <description>Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)</title>
          <description>Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 24. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7" spread="21.1"/>
                    <measurement group_id="O2" value="-29.3" spread="23.0"/>
                    <measurement group_id="O3" value="-23.6" spread="21.6"/>
                    <measurement group_id="O4" value="-32.4" spread="22.1"/>
                    <measurement group_id="O5" value="-24.9" spread="23.7"/>
                    <measurement group_id="O6" value="-23.8" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.432</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.04</ci_lower_limit>
            <ci_upper_limit>3.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.180</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.69</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.718</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.33</ci_lower_limit>
            <ci_upper_limit>7.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.54</ci_lower_limit>
            <ci_upper_limit>-1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.682</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.06</ci_lower_limit>
            <ci_upper_limit>5.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Medial Joint Space Width (mJSW) of the Target Knee</title>
        <description>Change from baseline in mJSW as documented by radiograph of the target knee.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medial Joint Space Width (mJSW) of the Target Knee</title>
          <description>Change from baseline in mJSW as documented by radiograph of the target knee.</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.72"/>
                    <measurement group_id="O2" value="-0.11" spread="0.53"/>
                    <measurement group_id="O3" value="-0.11" spread="0.92"/>
                    <measurement group_id="O4" value="-0.03" spread="0.45"/>
                    <measurement group_id="O5" value="-0.01" spread="0.60"/>
                    <measurement group_id="O6" value="-0.08" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.822</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)</title>
        <description>Change from baseline OA disease activity as assessed by PtGA at Week 24. The PtGA was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)</title>
          <description>Change from baseline OA disease activity as assessed by PtGA at Week 24. The PtGA was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="23.5"/>
                    <measurement group_id="O2" value="-19.8" spread="27.1"/>
                    <measurement group_id="O3" value="-11.9" spread="27.5"/>
                    <measurement group_id="O4" value="-18.3" spread="24.5"/>
                    <measurement group_id="O5" value="-13.0" spread="21.6"/>
                    <measurement group_id="O6" value="-13.8" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.36</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.80</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.552</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.36</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.16</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.887</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.79</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Pain in the Target Knee as Assessed by WOMAC Pain Subscore (WOMAC Pain)</title>
        <description>Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain, 100 = pain as bad as it can be].</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Pain in the Target Knee as Assessed by WOMAC Pain Subscore (WOMAC Pain)</title>
          <description>Change from baseline OA pain in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is standardized and reported ranging from 0 to 100 [0 = no pain, 100 = pain as bad as it can be].</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" spread="20.5"/>
                    <measurement group_id="O2" value="-29.3" spread="21.5"/>
                    <measurement group_id="O3" value="-22.1" spread="20.2"/>
                    <measurement group_id="O4" value="-32.1" spread="21.2"/>
                    <measurement group_id="O5" value="-23.7" spread="24.6"/>
                    <measurement group_id="O6" value="-22.8" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.473</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.99</ci_lower_limit>
            <ci_upper_limit>3.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.33</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.577</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.35</ci_lower_limit>
            <ci_upper_limit>7.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.90</ci_lower_limit>
            <ci_upper_limit>-3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.947</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.37</ci_lower_limit>
            <ci_upper_limit>5.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)</title>
        <description>Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)</title>
          <description>Change from baseline OA function in the target knee as assessed by WOMAC Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 12. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is standardized and reported ranging from 0 to 100 [0 = no functional disability, 100 = unable to function].</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.0" spread="19.0"/>
                    <measurement group_id="O2" value="-29.3" spread="21.8"/>
                    <measurement group_id="O3" value="-20.9" spread="20.2"/>
                    <measurement group_id="O4" value="-30.4" spread="21.3"/>
                    <measurement group_id="O5" value="-22.7" spread="23.2"/>
                    <measurement group_id="O6" value="-22.7" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.83</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.24</ci_lower_limit>
            <ci_upper_limit>-1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.75</ci_lower_limit>
            <ci_upper_limit>7.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.70</ci_lower_limit>
            <ci_upper_limit>-2.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.925</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.99</ci_lower_limit>
            <ci_upper_limit>6.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Pain in the Target Knee as Assesses by the Weekly Average of Daily Pain NRS</title>
        <description>Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 12. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Pain in the Target Knee as Assesses by the Weekly Average of Daily Pain NRS</title>
          <description>Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 12. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain (pain as bad as one can imagine).</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" spread="2.22"/>
                    <measurement group_id="O2" value="-3.02" spread="2.03"/>
                    <measurement group_id="O3" value="-2.21" spread="2.23"/>
                    <measurement group_id="O4" value="-2.87" spread="2.10"/>
                    <measurement group_id="O5" value="-2.15" spread="2.39"/>
                    <measurement group_id="O6" value="-2.27" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.693</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.697</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)</title>
        <description>Change from baseline OA disease activity as assessed by PtGA at Week 12. The PtGA completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O3">
            <title>0.15 mg SM04690</title>
            <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O4">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
          </group>
          <group group_id="O6">
            <title>Sham</title>
            <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Disease Activity as Assessed by Patient Global Assessment (PtGA)</title>
          <description>Change from baseline OA disease activity as assessed by PtGA at Week 12. The PtGA completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
          <population>Data is reported as observed with no imputation. Discrepancy between the number of participants analyzed and the number of participants assigned to the arms is the result of missing data and/or subject withdrawal.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" spread="25.0"/>
                    <measurement group_id="O2" value="-20.0" spread="28.0"/>
                    <measurement group_id="O3" value="-10.9" spread="23.4"/>
                    <measurement group_id="O4" value="-18.4" spread="24.9"/>
                    <measurement group_id="O5" value="-12.7" spread="21.9"/>
                    <measurement group_id="O6" value="-12.7" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.04</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.10</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.20</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.41</ci_lower_limit>
            <ci_upper_limit>-1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.74</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data regarding treatment-emergent adverse events (TEAEs) was collected in this study. TEAEs are events that occur during the course of the study that are not present prior to Day 1 study medication injection, or, if present at the time of study medication injection, have worsened in severity during the course of the study. TEAEs were assessed at each study visit from the time of study medication injection on study visit Day 1 through Week 24 (End-of-Study)/Early Termination.</time_frame>
      <desc>The Safety Analyses Set [SAS] includes all subjects who received a study injection, analyzed as treated. Discrepancy in subject counts between SAS and Full Analysis Set [FAS] is the result of subjects who received a treatment that is different from the planned treatment group as randomized. Subjects who received a study treatment not as prescribed in the pharmacy manual are summarized in the &quot;Other&quot; treatment group for safety analysis reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.03 mg SM04690</title>
          <description>Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="E2">
          <title>0.07 mg SM04690</title>
          <description>Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="E3">
          <title>0.15 mg SM04690</title>
          <description>Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="E4">
          <title>0.23 mg SM04690</title>
          <description>Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle</description>
        </group>
        <group group_id="E6">
          <title>Sham</title>
          <description>Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle</description>
        </group>
        <group group_id="E7">
          <title>Other</title>
          <description>Single intra-articular injection of an unidentified dose of SM04690 or Placebo due to incorrectly performed dilution or documentation by a pharmacist.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Swearingen, PhD, VP of Biometrics</name_or_title>
      <organization>Biosplice Therapeutics, Inc.</organization>
      <phone>858.926.2952</phone>
      <email>chris.swearingen@biosplice.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

